Evidence map›Paper›PMID 40098407›Full record

ArticleVirulence2025

Analysis of HIV-1 subtypes and drug resistance mutations in people who inject drugs in Aizawl and nearby districts of Mizoram, India.

Komal Raskar, Lal Thlengliani, Andrew Lalbiaknunga, Dipali Kale, Ajit Patil, Pragati Chavan, Richard Clr Hluna, Samiran Panda, Swarali Kurle

Abstract read
In one paragraph

Article in Virulence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Komal RaskarHIV Drug Resistance Laboratory, ICMR - National Institute of Translational Virology and AIDS Research, Pune, India.
Lal ThlenglianiMizoram State AIDS Control Society, Aizawl, India.
Andrew LalbiaknungaMizoram State AIDS Control Society, Aizawl, India.
Dipali KaleHIV Drug Resistance Laboratory, ICMR - National Institute of Translational Virology and AIDS Research, Pune, India.
Ajit PatilHIV Drug Resistance Laboratory, ICMR - National Institute of Translational Virology and AIDS Research, Pune, India.ORCID 0000-0002-6976-0978
Pragati ChavanHIV Drug Resistance Laboratory, ICMR - National Institute of Translational Virology and AIDS Research, Pune, India.
Richard Clr HlunaMizoram State AIDS Control Society, Aizawl, India.
Samiran PandaIndian Council of Medical Research, New Delhi, India.
Swarali KurleHIV Drug Resistance Laboratory, ICMR - National Institute of Translational Virology and AIDS Research, Pune, India.ORCID 0000-0001-6448-4823

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the last decade, there has been a steady increase in HIV-1 prevalence in Mizoram, India. Importantly, this increase in HIV-1 prevalence is not only limited to the key population groups such as female sex workers (FSWs) or people who inject drugs (PWID), and has been witnessed in general population as well. Injecting drug use has long been one of the key drivers of HIV-1 epidemic across the north-eastern states of India. In this study, using HIV-1 pol gene region sequences from Aizawl and adjoining districts, we examined the HIV-1 subtypes, recombinant forms, drug resistance mutations and also the spatiotemporal dynamics of the potential unique recombinant forms. In our dataset, the dominant subtype was HIV-1 subtype C (94.91%). We could also identify the presence of CRF01_AE (1.69%) and BC recombinant forms (3.39%). Drug resistance mutation analysis revealed that resistance against non-nucleoside reverse transcriptase inhibitors was most common in the sequences having any resistance mutations. Evolutionary analysis of unique BC recombinants estimated the most recent common ancestor of these sequences around 2004-2005 and them having an ancestry of United States of America (USA) origin.

Indexed as

Drug Resistance, ViralHIV-1HIV InfectionsSubstance Abuse, IntravenousAdultAnti-HIV AgentsFemaleGenotypeHumansIndiaMaleMutationPhylogenypol Gene Products, Human Immunodeficiency VirusPrevalenceRecombination, GeneticAnti-HIV Agentspol Gene Products, Human Immunodeficiency VirusDRMHIV-1MizoramPWIDrecombinants

Identifiers

PMID40098407
PMCPMC12915421

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.